Mindmaze Therapeutics Holding Sa · SIX:MMTX
Mindmaze Therapeutics Holding Sa — Investor Presentation (September 2026)
21 slides from Mindmaze Therapeutics Holding Sa's investor presentation, September 2026
Slide 1: Improving lives through precision neurotherapy: scaling care from hospital to home
Improving lives through precision neurotherapy: scaling care from hospital to home Investor presentation September 2026 · SIX: MMTX
Slide 2: Disclaimer
Disclaimer This presentation does not constitute or form part of any offer to sell or issue, or any solicitation of an offer to purchase or subscribe for, any securities. Neither this presentation nor its distribution shall form the basis of, or be relied upon in connection with, any contract or inv
Slide 3: Closing the neurorehabilitation delivery gap
UNMET NEED Closing the neurorehabilitation delivery gap The Therapy Gap The MindMaze Platform High need. Limited capacity. More therapy. For more patients. Everywhere. Evidence-based, gamified neurotherapy across the recovery journey 3+ hours/day 5 days/week Intensive, repetitive practice 80% of pat
Slide 4: Solid foundations, now converting into commercial traction
SWISS COMMERCIAL-STAGE NEUROTECHNOLOGY COMPANY Solid foundations, now converting into commercial traction 01 02 03 Established platform Commercial scale-up Multiple pathways to scale Expanded U.S. commercial team 35,000+ Channel partnerships Provider Life Sciences AI & Patients treated to date First
Slide 5: A large and growing neurological disease burden
DISEASE BURDEN A large and growing neurological disease burden Indication Prevalence Annual cost Growth CAGR 2024–34 >$1T Stroke ~7m $120bn ~4% Dementia, incl. Alzheimer’s ~6m $775bn ~4% Annual U.S. economic burden Traumatic brain and spinal injury ~6m $130bn ~3% Direct and indirect costs · 2024E Pa
Slide 6: An integrated neurorehabilitation platform from clinic to home
PRODUCT PLATFORM An integrated neurorehabilitation platform from clinic to home High-dose, high-intensity, gamified motor and cognitive therapy IN-CLINIC INPATIENT | OUTPATIENT | HOME Immersive room with motion tracking and Screen-based therapy with motion tracking interactive software for upper-lim
Slide 7: MindMotion Lite: Expanding neurorehabilitation at home
PRODUCT EXPANSION MindMotion Lite: Expanding neurorehabilitation at home The full range of MindMotion GO neurotherapeutic activities on a tablet Full-body therapy Preserves MindMotion GO’s full-body rehabilitation capabilities Connected care Supports teleconsultation and remote management by healthc
Slide 8: Extending high-intensity therapy across the continuum of care
CONTINUUM OF CARE Extending high-intensity therapy across the continuum of care Better outcomes, sustained over time MindMaze platform Illustrative functional performance Standard of care Pre-impact Impact Acute care Sub-acute Chronic Aging Inpatient Outpatient At home Recommended therapy schedule1
Slide 9: Robust clinical evidence across neurology
CLINICAL EVIDENCE Robust clinical evidence across neurology Cognition & Upper limb Gait & balance psychiatric 28 Clinical studies +19.6 pts Fugl-Meyer · in-clinic +7.3 pts -2 sec Dual-task timed up and go -41% +7 pts Neuropsychiatric index In-clinic and home-based settings Stroke, PD and at-risk agi
Slide 10: One platform, three pathways to scale
BUSINESS MODEL One platform, three pathways to scale Healthcare providers SELECTED CUSTOMERS AND PARTNERS U.S. priority · Commercial scale-up Rehabilitation across inpatient, outpatient and home settings. ~100 Hospitals and neurorehabilitation Revenue model: Recurring software subscriptions, combine
Slide 11: Vibra: scaling therapy across care settings
PROVIDER CASE STUDY Vibra: scaling therapy across care settings Cumulative patients across 5 Vibra centers since 2025 launch 524Inpatient 321 Home Multi-site commercial deployment 2.7x 80% of therapy dose delivered 82% Inpatient, outpatient and home · without a licensed therapist Across neurological
Slide 12: Slide 12
Slide 13: Expanding access through reimbursement
REIMBURSEMENT Expanding access through reimbursement United States Europe Established coding pathway Building reimbursement pathways At-home claims receiving Clinical programs generating payer reimbursement evidence across key markets Switzerland SwissNeuroRehab Category III CPT codes 0733T and 0734
Slide 14: Four routes to Life Sciences partnerships
LIFE SCIENCES Four routes to Life Sciences partnerships Clinical trial Portfolio Combination Combination optimization expansion with devices with drugs Digital assessment and training Add MindMaze solutions to drug Combine digital neurotherapy Combine digital neurotherapy for more efficient trials a
Slide 15: Proprietary data creates additional AI optionality
AI PLATFORM Proprietary data creates additional AI optionality Existing foundations Under evaluation Longer-term 1.2bn Monthly data points Patient and therapist assistance Personalized and autonomous therapy Validated deterministic Patient virtual advisor Generative AI for patient-personalized exper
Slide 16: Potential to exceed CHF 200m in annual revenue by 2031
REVENUE POTENTIAL Potential to exceed CHF 200m in annual revenue by 2031 Healthcare providers Life Sciences AI & data platform 75-125m CHF 50-100m CHF Additional Personalized and upside autonomous therapy U.S. priority · Global expansion Global partnerships Longer-term opportunity Expand deployment
Slide 17: 2026 execution: progress and next milestones
STRATEGIC EXECUTION 2026 execution: progress and next milestones 2026 progress to date Next milestones U.S. commercial team expanded; Vibra channel partnership Convert provider pipeline into customer contracts Commercial established; commercial pipeline built MindMotion Lite launch expected by year-
Slide 18: Leadership expertise across healthcare and technology
LEADERSHIP Leadership expertise across healthcare and technology Executive Management Team Zach Henderson Alexander Capet Frederic Condolo Jeremy Meinen CEO & Director COO CTO CFO Board of Strategic Directors advisor Walid Nazir Hanna Olaf Blanke Martin Reiss Prof. John Krakauer Chairman Director Di
Slide 19: Corporate profile
INVESTOR INFORMATION Corporate profile Operating footprint Listing & capital structure SIX SWISS EXCHANGE U.S. OTCQB HEADQUARTERS Geneva, Switzerland MMTX MMTZF U.S. ADR program supporting a potential future U.S. listing. U.S. COMMERCIAL HUB Charlotte, North Carolina Shares outstanding ESOP & RSUs W
Slide 20: A different platform with the foundations to scale
INVESTMENT CASE A different platform with the foundations to scale Structural Integrated Clinical Commercial Multiple unmet need platform evidence foundations pathways to scale Growing In-clinic and 28 clinical studies U.S. commercial Provider expansion, neurological at-home solutions across neurolo
Slide 21: Geneva · Lausanne · Charlotte, NC
Geneva · Lausanne · Charlotte, NC ir@mindmazetherapeutics.com
MindMaze Therapeutics Holding — Investor Presentation (September 2026) on 6ix